Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Tsuboi, M. [2 ]
Wu, Y. [3 ,4 ]
John, T. [5 ]
Majem, M. [6 ]
Wang, J. [7 ]
Kato, T. [8 ]
Goldman, J. [9 ]
Kim, S. [10 ]
Yu, C. [11 ,12 ]
Vu, H. [13 ]
Mukhametshina, G. [14 ]
Akewanlop, C. [15 ]
de Marinis, F. [16 ]
Shepherd, F. [17 ]
Urban, D. [18 ,19 ]
Stachowiak, M. [20 ]
Balanos, A. [20 ]
Huang, X. [20 ]
Herbst, R. [21 ,22 ]
Kern, J. [15 ,23 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Berlin, Germany
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[4] Guangdong Acad Med Sci, Guangzhou, Peoples R China
[5] Austin Hlth, Heidelberg, Australia
[6] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[7] Chinese Acad Med Sci, Beijing, Peoples R China
[8] Kanagawa Canc Ctr, Asahi Ward, Asahi, Japan
[9] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[10] Asan Med Ctr, Seoul, South Korea
[11] Natl Taiwan Univ Hosp, Taipei, Taiwan
[12] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[13] Cho Ray Hosp, Ho Chi Minh City, Vietnam
[14] Republican Clin Oncol Ctr, Kazan City, Russia
[15] Siriraj Hosp, Bangkok, Thailand
[16] IRCCS, European Inst Oncol Ieo, San Giovanni Rotondo, Italy
[17] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON, Canada
[18] Sheba Med Ctr, Tel Hashomer, Israel
[19] Sackler Fac Med, Tel Hashomer, Israel
[20] Astrazeneca, Cambridge, England
[21] Yale Sch Med, New Haven, CT USA
[22] Yale Canc Ctr, New Haven, CT USA
[23] Kwm Missio Clin, Wurzburg, Germany
来源：
PNEUMOLOGIE | 2023年 / 77卷
关键词：
D O I：
10.1055/s-0043-1760904
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
FV 96
引用
收藏
页码：S17 / S17
页数：1
相关论文
共 50 条
  • [41] Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)
    Kenmotsu, Hirotsugu
    Sugawara, Shunichi
    Watanabe, Yasutaka
    Saito, Haruhiro
    Okada, Morihito
    Chen-Yoshikawa, Toyofumi Fengshi
    Ohe, Yuichiro
    Nishio, Wataru
    Nakagawa, Shizuka
    Nagao, Haruka
    CANCER SCIENCE, 2022, 113 (12) : 4327 - 4338
  • [42] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
    Shu-Ling Zhang
    Xiao-Fang Yi
    Le-Tian Huang
    Li Sun
    Jie-Tao Ma
    Cheng-Bo Han
    BMC Cancer, 23
  • [43] Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
    Zhang, Shu-Ling
    Yi, Xiao-Fang
    Huang, Le-Tian
    Sun, Li
    Ma, Jie-Tao
    Han, Cheng-Bo
    BMC CANCER, 2023, 23 (01)
  • [44] Physician referral patterns and use of adjuvant therapy among stage IB-IIIA non-small cell lung cancer (NSCLC) patients (2010-2017).
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Chirikov, Viktor
    Shah, Anne
    Apple, Jon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results
    Altorki, N. K.
    O'brien, M. E. R.
    Eberhardt, W. E. E.
    Richardson, F. C.
    Wang, J.
    Foley, M. A.
    Horan, J. D.
    Shepherd, F. A.
    Kelly, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S3
  • [46] Assessing the predictive value of ctDNA on relapse in patients with resected stage IB-IIIA NSCLC treated with adjuvant chemotherapy plus concomitant atezolizumab followed by atezolizumab: BTCRC LUN 19-396.
    Ardeshir-Larijani, Fatemeh
    Mohindra, Nisha Anjali
    Traynor, Anne M.
    Malhotra, Jyoti
    Shum, Elaine
    Ma, Patrick C.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC
    Varlotto, J.
    Wang, Y.
    Sun, Z.
    Wakelee, H.
    Ramalingam, S.
    Schiller, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S944 - S944
  • [48] Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).
    Jung, Hyun Ae
    Jeon, Yeong Jeong
    Kim, Jhingook
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Comparison of individual patient data from real-world experience with the ADAURA study for resected stage IB-IIIA EGFR-mutated non-small cell lung cancer
    Jung, Hyun Ae
    Lee, Junho
    Park, Boram
    Park, Sehhoon
    Sun, Jong-Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    CANCER RESEARCH, 2024, 84 (06)
  • [50] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Felip, E.
    Vallieres, E.
    Zhou, C.
    Wakelee, H.
    Bondarenko, I.
    Sakai, H.
    Saito, H.
    Ursol, G.
    Kawaguchi, K.
    Liu, Y.
    Levchenko, E.
    Kislov, N.
    Reck, M.
    Liersch, R.
    McNally, V. A.
    Zhu, Q.
    Ding, B.
    Bennett, E.
    Gitlitz, B.
    Altorki, N. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
12345